Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-3310 in Healthy Subjects and CKD Patients With Type 2 Diabetes Mellitus
NCT07619157Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of ONO-3310 in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events at 74 days, Maximum plasma observed concentration at 74 days and 8 more. Started Jun 2026; status: recruiting.
02
Drugs
ONO-3310
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07619157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619157.